A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria by unknown
RESEARCH ARTICLE Open Access
A double-blind, randomized, placebo-
controlled trial of combined calcitriol and
ergocalciferol versus ergocalciferol alone in
chronic kidney disease with proteinuria
Paweena Susantitaphong*, Siriwan Nakwan, Sadudee Peerapornratana, Khajohn Tiranathanagul, Pisut Katavetin,
Nattachai Srisawat, Kearkiat Praditpornsilpa and Somchai Eiam-Ong
Abstract
Background: KDOQI guideline suggests that nutritional vitamin D should be supplemented in chronic kidney
disease (CKD) patients who have vitamin D insufficiency/deficiency. However, there are scarce data regarding the
additional benefit of active vitamin D supplement in CKD patients who were receiving nutritional vitamin D
supplement. This study was conducted to explore the effect of adding active vitamin D to nutritional vitamin D
supplement on proteinuria and kidney function in CKD with vitamin D insufficiency/deficiency.
Methods: This double-blind, randomized placebo-controlled trial was performed to answer the above question.
Sixty-eight patients with CKD stage 3–4, urine protein to creatinine ratio (UPCR) > 1 g/g, and serum 25OH-D level
< 30 ng/mL were enrolled. Patients were randomly assigned to receive 12-week treatment with oral ergocalciferol
plus placebo (n = 36) or oral ergocalciferol plus calcitriol (n = 32).
Results: The mean baseline values of UPCR of both groups were comparable (3.6 ± 3.8 g/g in combined group
and 3.5 ± 3.0 g/g in ergocalciferol group). Following 12-week treatment, there were significant reductions in UPCR from
baseline in both groups (2.3 ± 2.1 g/g in combined group and 2.4 ± 2.0 g/g in ergocalciferol group). The percentage
reductions in UPCR of both groups were not significantly different. The mean eGFR and blood pressure did not differ
between baseline and 12-week follow-up and between both groups. No severe hypercalcemia or serious side effects
were noted in both groups.
Conclusions: The proteinuria lowering effect of ergocalciferol in CKD patients with vitamin D deficiency was
demonstrated. Additional calcitriol supplement did not have more effects on proteinuria.
Trial registration: (Thai Clinical Trials Registry (TCTR) 20140929002). Date of registration: September 27, 2014.
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Background
Chronic kidney disease (CKD) is one of the most
extremely important non-communicable diseases that
has significant morbidity and mortality consequences
[1]. The major complications related to CKD include
cardiovascular disease, infectious complications, and
mineral and bone disorder (MBD). A recent meta-
analysis demonstrated that lower estimated glomerular
filtration rate (eGFR) and higher albuminuria were each
independently associated with end-stage renal disease
(ESRD) and mortality. Both eGFR and albuminuria were
more strongly associated with ESRD than mortality in
CKD patients [2].
Vitamin D deficiency/insufficiency is a common problem
in CKD patients due to dysregulation of vitamin D metab-
olism from renal insufficiency [3]. Although the definite
critical serum 25 (OH) D level and benefits of 25 (OH) D
supplement in CKD patients remain controversial, In the
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2003 Kidney Disease Outcomes Quality Initiative (KDOQI)
guideline suggested that patients with serum 25(OH) D
levels < 30 ng/mL should receive supplementation with
nutritional vitamin D. The dosage regimens were recom-
mended to be the same as general population [4].
Besides the classical action of vitamin D as an important
regulator of mineral bone metabolism, recent evidence
points to other important functions in different target
organs including renal, cardiovascular systems, and im-
mune response regulation [5]. Vitamin D deficiency was
associated with a higher annual incidence of albuminuria,
decreased eGFR, and independently predicted 5-year
incidence of albuminuria [6]. Vitamin D deficiency was
also a significant risk factor for the development of
CKD stage 3–5 [7, 8]. In addition, vitamin D deficiency
is independently associated with a higher risk of 50%
increase in baseline serum creatinine, ESRD, or death
in patients with type II diabetic nephropathy (DN) [9].
Previous cohort studies showed that daily cholecalciferol,
a nutritional vitamin D, supplement had a beneficial effect
in decreasing albuminuria in CKD and DN [10, 11].
Active vitamin D has been demonstrated to lessen
renin-angiotensin aldosterone system (RAAS) and intra-
glomerular pressure, and might ameliorate renal injury by
reducing fibrosis, apoptosis, and inflammation in animal
models [12]. Several randomized controlled trials in
patients with proteinuric kidney disease demonstrated the
benefit of calcitriol or paricalcitol supplement in decreas-
ing proteinuria [13–15]. However, there were no random-
ized controlled trials (RCTs) exploring the effect of the
additional benefit of active vitamin D supplement in CKD
patients who were receiving nutritional vitamin D supple-
ment. Therefore, this study was conducted to explore the
effect of combined nutritional vitamin D and active vita-
min D supplement on proteinuria and kidney function in
CKD with vitamin D insufficiency/deficiency.
Methods
Study design and participants
The study was performed during July 2014 and February
2015 in adult Thai CKD patients with proteinuria and
vitamin D insufficiency/deficiency at the outpatient clinic
at King Chulalongkorn Memorial Hospital (KCMH),
Bangkok, Thailand. The study was approved by the
Institutional Review Board of the Faculty of Medicine,
Chulalongkorn University (Bangkok, Thailand; IRB.093/57)
with clinical trial registration (Thai Clinical Trials Registry
(TCTR) 20140929002; date of registration: September 27,
2014). All participants received information of study details
before giving written informed consent. The inclusion cri-
teria included eGFR of 15–60 mL/min per 1.73 m2, age
18 years or older, proteinuria greater than 1 g/day, and
serum vitamin D (25-OH) level less than 30 ng/mL. The
eGFR was calculated with serum creatinine concentrations
by using Thai-MDRD formula [16]. Exclusion criteria
included active glomerulonephritis, receiving immunosup-
pressive drugs within 3 months before enrollment, adjust-
ing RAAS blockade such as angiotensin-converting-enzyme
inhibitors or angiotensin II receptor blockers (ACEIs/ARBs)
within 3 months before enrollment, and serum calcium
level more than 10.2 mg/dL.
This study was a double-blind RCT of ergocalciferol, a
nutritional vitamin D, with or without calcitriol, an ac-
tive vitamin D, in CKD with proteinuria and vitamin D
insufficiency/deficiency. We randomly assigned eligible
patients in a 1:1 ratio to 40,000 units/week of ergocalcif-
erol plus identical placebo or 40,000 units/week of ergo-
calciferol plus calcitriol (0.5 μg, two times per week) for
12 weeks.
Patients were examined at baseline, 6-week, and 12-week.
Blood pressures, adverse events, concomitant drug treat-
ment, and adherence to drug regimens were also recorded.
At baseline, 6-week, and 12-week, the blood chemistry pa-
rameters including serum creatinine, cystatin C, calcium,
phosphate, albumin, intact parathyroid hormone (iPTH)
were measured while urine specimen collection at first void
urine including urine protein to creatinine ratio (g/g) were
determined. The dosages of ACEIs or ARBs were not
allowed to adjust during the follow-up period. Other anti-
hypertensive treatments were initiated or increased in dose
for controlling blood pressure following the KDIGO guide-
line (<130/80 mmHg) [17].
Randomization and masking
Computer-generated concealed randomization schedules,
each with permuted block sizes of four, were created.
When an eligible patient had been enrolled, the research
assistant used sealed opaque envelopes to allocate the pa-
tient to the next sequential randomization number. This
study was double blinded. Patients were not informed
which group they were randomly allocated to. The labora-
tory personnel processing the samples also had no know-
ledge of each patient’s group assignment. The physicians
who took care of the patients were also masked.
Outcomes
The primary endpoint was the percentage change in
urine protein to creatinine ratio (UPCR) which was cal-
culated by using the values obtained at baseline and after
12 weeks of follow-up period. Secondary endpoints were
the proportion of patients who achieved at least 30% re-
duction in UPCR, the change of kidney functions, blood
pressure level, and blood chemistry. The safety end-
points and all adverse events were classified and con-
firmed by personals who were masked to treatment
assignment.
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Statistical analysis
The aim of this study was to determine the effect of
additional calcitriol supplement in CKD patients who
were receiving ergocalciferol supplement on protein-
uria. As there were no published RCTs, we calculated
and found that a sample size of 35 patients per arm
was needed for 80% power to detect a difference in
proteinuria of −1.0 g/g [standard deviation (SD) 1.5]
between ergocalciferol alone and ergocalciferol plus calci-
triol group with two-sided significance level of 0.05. The
expected reduction in a urine proteinuria was based on
our own clinical setting. The per protocol analysis was
used for all efficacies and safety analyses. Patients who lost
follow up and had some missing data for calculating the
change values in the efficacy and safety measures between
two time points were excluded from the analyses. Con-
tinuous variables were reported as mean ± standard devi-
ation. Categorical variables were reported in terms of
frequency and percentage. For normally distributed vari-
able, the differences in changes between the two groups
were analyzed by unpaired t-test. The differences in
changes within groups were analyzed by pair t-test. For
non-normally distributed variable, Mann–Whitney U-test
was used to analyze differences between the two groups.
Categorical outcomes were analyzed by chi-square or
Fisher exact test. The statistical analyses were performed
by using the SPSS version 16.0 statistical software
program.
Results
Of 112 eligible patients, 74 were enrolled and randomly
assigned to ergocalciferol plus calcitriol (combined group,
n = 36) or ergocalciferol plus placebo (ergocalciferol group,
n = 38). All randomly assigned patients received their allo-
cated treatment and had at least one post-randomization
follow-up visit. Two patients were lost to follow-up in ergo-
calciferol group and 4 patients in combined group (Fig. 1).
Baseline demographic, clinical and biochemical char-
acteristics, and concomitant treatments were balanced
between both groups. The main cause of CKD was DN
(57.4%). The participants randomly allocated to the
ergocalciferol group were more likely to have lower
serum 25 (OH) D levels than those in the combined
group (Table 1).
Effect on proteinuria
The mean baseline values of UPCR of both groups were
comparable (3.6 ± 3.8 g/g in combined group and 3.5 ±
3.0 g/g in ergocalciferol group). After 12-week treatment,
there were significant reductions of UPCR in both groups
(2.3 ± 2.1 g/g in combined group and 2.4 ± 2.0 g/g in ergo-
calciferol group) (Fig. 2). The percentage reductions in
UPCR of both groups were not significantly different
(−25.5%, 95% CI −9.2 to −41.8 in combined group,
−23.7%; 95% CI −7.0 to −40.5 in ergocalciferol group).
More than 50% of patients had 30% reduction on protein-
uria in both groups (56.3% in combined group and 52.8%
in ergocalciferol group).
Subgroup analysis by cause of CKD, the level of pro-
teinuria, and status of receiving RAAS blockade were
performed. The mean change in UPCR from baseline to
the end of treatment in DN seemed to be greater than
non-DN [−31.3% vs. -15.3% in ergocalciferol group; and
−28.1% vs −21.2% in combined group] (Fig. 3a). In
addition, the mean change in UPCR seemed to be more
robust in case of nephrotic range proteinuria than non-
Allocated to  receive 
ergocalciferol plus placebo
N=38
Allocated to  receive 
ergocalciferol plus calcitriol
N=36
Block of 4 
randomization
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:Not meeting inclusion 
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74 enrolled and 
randomly 
assigned







32 completed the study36 completed the study
Fig. 1 Flow diagram showing recruitment and follow-up of patients
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nephrotic range [−38.7% vs −14.2% in ergocalciferol
group; and −28.7% vs −23.8% in combined group
(Fig. 3b). However, the mean changes in UPCR in whom
receiving RAAS blockade or non-receiving RAAS block-
ade were not significantly different. [−30.6% vs −16.9%
in ergocalciferol group; and −17.2% vs −36.2% in com-
bined group] (Fig. 3c).
Effect on kidney function
eGFR determined by serum creatinine (Thai MDRD)
and by cystatin C (CKD-EPI) did not change during the
study period from baseline to the end of treatment and
there were no significant differences between the ergo-
calciferol group and the combined group (Fig. 4).
Effect on blood pressure
There were no significant changes in mean systolic and
diastolic blood pressure values throughout the course of
study in either ergocalciferol group or combined group.
Mean blood pressure values at baseline were 136.7 ±
14.6/75.8 ± 10.5 mmHg in the ergocalciferol group and
137.8 ± 14.8/77.1 ± 11.7 mmHg in the combined group
(NS). At the end of treatment, mean blood pressure
values were 135.6 ± 17.4/77.9 ± 11.2 mmHg in the ergo-
calciferol group and 135.8 ± 20.0/77.9 ± 11.9 mmHg in
the combined group.
Effect on metabolic bone disease
There were no significant changes of serum calcium,
serum phosphate from baseline to the end of treatment
as well as between both groups [9.4 ± 0.5 to 9.3 ±
0.6 mg/dL and 3.6 ± 0.6 to 3.8 ± 0.7 mg/dL in ergocalcif-
erol group, 9.3 ± 0.5 to 9.2 ± 0.5 mg/dL and 3.8 ± 0.8 to
3.8 ± 0.6 mg/dL in combined group]. No severe hyper-
calcemia, hyperphosphatemia, or serious side effects
were noted in both groups (NS).
There were no significant differences between iPTH
levels measured at baseline between two groups. Serum
iPTH was slightly increased from 85.1 ± 47.4 pg/mL at
baseline to 86.0 ± 46.0 pg/mL (P = 0.83) at the end of
Table 1 Baseline characteristics of the study population
Demographic Ergocalciferol plus placebo (n = 36) Ergocalciferol plus calcitriol (n = 32) P-value
Age (years) 62.56 ± 12.91 63.13 ± 11.29 0.85
Male sex (%) 15 (41.67) 17 (53.13) 0.35
Cause of CDK
− Diabetic nephropathy 19 (52.78) 20 (62.5) 0.43
− Chronic glomerulonephritis 4 (11.11) 4 (12.5) 0.88
− IgA nephropathy 1 (2.78) 2 (6.25) 0.48
− Focal segmental glomerulosclerosis 3 (8.33) 1 (3.13) 0.35
− Polycystic kidney disease 1 (11.11) 0 (0) 0.31
− Unknown 8 (22.22) 5 (15.63) 0.49
Blood pressure (mmHg)
− Systolic 136.69 ± 14.56 137.75 ± 14.78 0.77
− Diastolic 75.75 ± 10.46 77.13 ± 11.68 0.61
Serum creatinine (mg/dL) 2.19 ± 0.9 2.43 ± 0.9 0.29
eGFR (ml/min/1.73 m2) 39.29 ± 11.26 37.29 ± 11.44 0.47
Serum cystatin C (mg/L) 2.07 ± 0.61 2.13 ± 0.67 0.70
25-hydroxy vitamin D level (ng/ml) 15.89 ± 6.59 19.26 ± 5.12 0.02
Urine protein to creatinine ratio (g/g)
− mean ± SD 3.47 ± 3.01 3.61 ± 3.75 0.87
Serum calcium (mg/dl) 9.4 ± 0.49 9.27 ± 0.47 0.27
Serum phosphorus (mg/dl) 3.58 ± 0.58 3.8 ± 0.78 0.17
Serum albumin (g/dl) 3.83 ± 0.42 3.95 ± 0.34 0.21
Serum intact parathyroid hormone (pg/mL) 85.11 ± 47.42 88.57 ± 64.49 0.60
Serum HbA1C (%) 7.17 ± 0.78 7.40 ± 0.59 0.31
Antihypertensive drug (%)
− ARB 8 (22.22) 11 (34.38) 0.27
− ACE inhibitor 10 (27.78) 8 (25) 0.79
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treatment in the ergocalciferol group and was signifi-
cantly decreased from 88.6 ± 64.5 to 73.9 ± 73.3 pg/mL
(P = 0.04) in the combined group. Serum iPTH levels in
the combined group were significantly lower than the
ergocalciferol group at the end of treatment (P = 0.03).
Vitamin D levels (25(OH)D) were significantly in-
creased from baseline to the end of treatment in both
ergocalciferol group (15.9 ± 6.6 to 30.6 ± 11.9 ng/mL)
and combined group (19.5 ± 5.2 to 33.4 ± 11.3 ng/mL),
but no statistical significance was observed between both
groups.
Discussion
This study was the first double-blind RCT to explore the
additional benefit of calcitriol supplement in CKD pa-
tients who were receiving ergocalciferol supplementation
on proteinuria and kidney function by using serum
cystatin C in CKD patients with vitamin D insufficiency/
deficiency. The study demonstrated that the 12-week
course of ergocalciferol supplementation in patients with
stage 3–4 CKD and nutritional vitamin D insufficiency/
deficiency could improve proteinuria as well as restored
25-vitamin D concentrations. Nevertheless, adding calci-
triol to ergocalciferal treatment did not provide further
beneficial effect for proteinuria (Fig. 2). Moreover, the
kidney function monitored by serum creatinine-based
and cystatin C-based eGFR did not significantly change
from the baseline to the end of treatment in both groups
and there were no significant differences between the
two groups (Fig. 4). No severe hypercalcemia or serious
side effects were noted in both ergocalciferol and com-
bined groups. In addition, blood pressure and glycemic
control were not significantly different between two
groups.
Although several observational studies in CKD patients
have shown the benefit of nutritional vitamin D
supplementation in decreasing proteinuria [10, 11], there
were no RCTs exploring the benefit of nutritional vitamin
D on proteinuria and renal functions. This RCT demon-
strates the benefit of nutritional vitamin D supplement in
proteinuric CKD with vitamin D insufficiency/deficiency
on proteinuria. The potential mechanisms remain to be
further explored. One possible mechanism is that normal
ranges of 25-(OH) D level achieved by ergocalciferol sup-
plement might be changed to the active form and could
activate VDR.
Several previous RCTs of proteinuric kidney disease
demonstrated the beneficial effect of calcitriol or parical-
citol supplement on decreasing proteinuria [13–15].
However, there is some inconsistency of the evidence. In
RCT of selective vitamin D receptor activation with pari-
calcitol for reduction of albuminuria in patients with
type 2 diabetes (VITAL study), paricalcitol could not
demonstrate an additional effect in decreasing albumin-
uria in DN patients [18]. The different dosage regimens
and the levels of proteinuria might affect the results. In-
deed, in a recent systematic review and meta-analysis,
active vitamin D, vitamin D compounds, and nutritional
vitamin D showed antiproteinuric effect in CKD patients
[19, 20]. However, these are no available data regarding
the role of combined nutritional vitamin D and active
vitamin D on proteinuria and renal function in CKD
patients with vitamin D insufficiency/deficiency. In
the present study, the combined ergocalciferol and
calcitriol also resulted in decreasing proteinuria from
baseline while the additional effect of combined nutri-
tional and active vitamin D could not be demon-
strated (Fig. 2). Admittedly, the long-term benefit of
combined ergocalciferol and calcitriol was not explored
in this study.
As such, the present study demonstrates that whenever
nutritional vitamin D is supplemented until achieving the
target level, the agent can decrease proteinuria. Vitamin
D and its analogues appear to have similar antiprotei-
nuric effects through activation of the VDR by several
mechanisms. Active vitamin D acts as a strong negative
endocrine regulator of the RAAS and functions mainly
to suppress renin production in experimental studies
[21, 22]. Inactive vitamin D and its metabolites (such as
25(OH) D and 24,25 (OH)2 D) might also have add-
itional effect on proximal tubular cells. 25(OH) D
bound to vitamin D binding protein is endocytosed by
megalin-cubilin in the apical membrane of proximal
tubular cells. Then, intracellular 25(OH) D is metabo-
lized to 1, 25(OH) 2D (calcitriol) by 1-α-hydroxylase in
the tubular cell [23]. Furthermore, vitamin D has been
shown to have anti-fibrotic and immunomodulatory ef-
fects by attenuating fibrotic and inflammatory markers
in animal and clinical studies [24–26]. The potential























Fig. 2 The absolute net change of UPCR from baseline to 12 weeks
follow-up between both groups *P-value when compared with baseline
in ergocalciferol group # P-value when compared with baseline
in combined group
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In term of kidney function, vitamin D compounds could
not demonstrate the benefit on renal function in CKD
patients in a recent systematic review and meta-analysis
[19, 20]. However, the renal function in all included
studies was determined by serum creatinine-based for-
mula which might be interfered by increasing muscle
mass from vitamin D supplement. New biomarkers such
as serum cystatin C should be used for more accurate
renal function measurement. Although the serum cystatin
C was used for calculating eGFR in this study (Fig. 4), the
benefits of kidney function after vitamin D supplement
were still not proven. A longer study might be re-
quired to examine the renal function retardation effect of

















































Fig. 3 The percentage change of UPCR from baseline to 12 weeks follow-up between both groups. Subgroup analyses by cause of CKD (3A),
Level of proteinuria (3B), Receiving RAAS (3C)
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Regarding metabolic bone disease, although serum cal-
cium and phosphate levels did not change during the
treatment in both groups, the benefit of controlling
serum iPTH was demonstrated only in the calcitriol
group. Therefore, active vitamin D compound should be
used in CKD if the goal is to treat secondary hyperpara-
thyroidism. There are some limitations of the present
analysis including small sample size that might result
from unexpected high standard deviation, the method of
urine protein measurement, office blood pressure moni-
toring, and short-term follow up.
Finally, according to the 2003 KDOQI guideline, it re-
mains controversial regarding the definite critical serum
25 (OH) D level and benefits of 25 (OH) D supplements
in CKD patients [3]. The guideline only mentioned that
whenever serum 25(OH) D levels < 30 ng/mL, supple-
mentation with nutritional vitamin D should be initiated
using dosing regimens recommended for the general
population. The first line use of ergocalciferol or chole-
calciferol was recommended due to less hypercalcemia
and hyperphosphatemia [4]. In another guideline, the
Kidney Disease: Improving Global Outcomes (KDIGO)
guideline [27] also provided opinion-based recommen-
dations regarding measurement of 25(OH) D in patients
with CKD. KDIGO recommended correcting 25(OH) D
deficiency or insufficiency using treatment strategies
used for the general population. Although ergocalciferol-
prescribing strategy in hemodialysis patients with vita-
min D insufficiency/deficiency using the KDOQI and
KDIGO guidelines is inadequate to achieve repletion or
maintenance of normal vitamin D levels [28], the ergo-
calciferol dosing in this study can improve and maintain
vitamin D status in CKD patients.
Conclusions
The effect of ergocalciferol to lower proteinuria in CKD
patients with vitamin D deficiency was demonstrated in
this RCT. However, additional calcitriol did not have
more proteinuria-lowering effects. Therefore, ergocalciferol
should be added for more decreasing proteinuria in CKD
patients with proteinuria that cannot tolerate or increase
the dosage of RAAS blockade due to any side effects.
However, there are some limitations of the present analysis
including small sample size and short-term follow up that
might result in non-significance on renal function.
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